National Vision (EYE) Competitors

National Vision (NASDAQ:EYE) and Soleno Therapeutics (NASDAQ:SLNO) are both consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.

Is EYE or SLNO more profitable?

Soleno Therapeutics has a net margin of 0.00% compared to National Vision's net margin of -0.81%. National Vision's return on equity of 3.52% beat Soleno Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	-0.81%	3.52%	1.39%
Soleno Therapeutics	N/A	-61.99%	-55.21%

Do analysts rate EYE or SLNO?

National Vision presently has a consensus price target of $14.00, indicating a potential upside of 13.36%. Soleno Therapeutics has a consensus price target of $104.67, indicating a potential upside of 39.82%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Soleno Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Which has preferable earnings & valuation, EYE or SLNO?

Soleno Therapeutics has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$1.82B	0.53	-$65.90M	-$0.36	-34.31
Soleno Therapeutics	N/A	N/A	-$38.99M	-$4.26	-17.57

Does the MarketBeat Community believe in EYE or SLNO?

Soleno Therapeutics received 67 more outperform votes than National Vision when rated by MarketBeat users. Likewise, 72.62% of users gave Soleno Therapeutics an outperform vote while only 64.80% of users gave National Vision an outperform vote.

Company	Underperform	Outperform
National Vision	Outperform Votes 254 64.80%	Underperform Votes 138 35.20%
Soleno Therapeutics	Outperform Votes 321 72.62%	Underperform Votes 121 27.38%

Do institutionals & insiders believe in EYE or SLNO?

97.4% of Soleno Therapeutics shares are owned by institutional investors. 2.3% of National Vision shares are owned by company insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, EYE or SLNO?

National Vision has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.29, meaning that its stock price is 329% less volatile than the S&P 500.

Does the media favor EYE or SLNO?

In the previous week, Soleno Therapeutics had 5 more articles in the media than National Vision. MarketBeat recorded 14 mentions for Soleno Therapeutics and 9 mentions for National Vision. Soleno Therapeutics' average media sentiment score of 1.11 beat National Vision's score of 1.06 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Vision	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soleno Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Soleno Therapeutics beats National Vision on 13 of the 18 factors compared between the two stocks.